ALIM - Alimera Sciences, Inc. Forward P/S Multiple

Alimera Sciences, Inc. (ALIM) - corporate logo

Optimized international drug delivery ensures stable access to Alimera Sciences products. The forward P/S ratio trend confirms market expectations, where 2.90 shows the value of this parameter. Revenues are based on the sale of Iluvien implants for retinal treatment, while the company implements ESG standards by reducing water consumption and improving packaging sustainability.

ALIM Alimera Sciences, Inc.: Forward Price-to-Revenue Multiple in the range 07/04/2022 - 09/21/2024

Comprehensive metric breakdowns and analytics for alimerasciences.com (ALIM)

- market price and analyst price targets:
Price Chart Alimera Sciences, Inc.|ALIM - Price Target Chart
- market capitalization statistics:
Market Capitalization ALIM|ALIM - Company Buyout Price
- issuer book value statistics:
Net Assets per Single Share Alimera Sciences|ALIM - Company Net Assets|Market Capitalization to Book Value Ratio alimerasciences.com|ALIM - Company Assets
- company liabilities and liquidity data:
Debt to Equity Alimera Sciences|ALIM - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Alimera Sciences, Inc.|ALIM - Company Aggregate Debts|Debt to Book Value ALIM|ALIM - Company Long-Term Loans and Borrowings|Company Short-Term Debt Alimera Sciences|Quick Ratio alimerasciences.com
- business earnings and investment ratios data:
ALIM - Net Income|Projected Future Earnings Alimera Sciences|ALIM - Business Payback Period|Forward P/E Multiple Alimera Sciences, Inc.|ALIM - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ALIM|ALIM - Operating profit before amortization|Net earnings per share (EPS TTM) Alimera Sciences|ALIM - Net earnings per share for the last 12 months|Quarterly EPS earnings growth alimerasciences.com|ALIM - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Alimera Sciences
- sales and revenue data:
ALIM - Company Gross Revenue|Projected Sales Volume Alimera Sciences, Inc.|ALIM - P/S Multiple|Price-to-Projected Revenue Ratio ALIM
Fundamental company analysis:Alimera (ALIM)
Original product of alimerasciences.com

Forward P/S determines the market value of an asset relative to projected annual revenue, allowing the forward P/S trend to identify deviations of the current price from fundamental value. This ratio correlates market capitalization with expected sales, which is critical for Alimera Sciences (ALIM) when assessing the efficiency of implementing robotics and AI in drug packaging to reduce operating expenses.

Key competitors

Price-to-Projected Revenue Ratio Alcon ALC|Bausch & Lomb - Price-to-Projected Revenue Ratio|Glaukos Corp. - Forward P/S Multiple|Market Cap to Expected Sales Ratio Apellis Corp APLS|belitebio.com (BLTE) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple ocutx.com|HROW (Harrow) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Viridian Therapeutics Inc VRDN|Price-to-Projected Revenue Ratio LENZ Pharma (LENZ)|OCS (Oculis Pharma) - Forward Price to Sales|Forward P/S Multiple EYPT (EyePoint Pharmaceuticals)|Forward P/S Multiple kodiak.com KOD|ALDX: Forward Price-to-Revenue Multiple|Forward Price to Sales KALA (KALA BIO, Inc.)|opusgtx.com (IRD) - Price-to-Projected Revenue Ratio|OKYO - Market Cap to Expected Sales Ratio|ADVM (Adverum Biotechnologies Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple outlooktherapeutics.com (OTLK)|Forward P/S Multiple CLSD|Market Cap to Expected Sales Ratio novabay.com|Forward P/S Multiple KPRX (Kiora Pharmaceuticals, Inc.)|Eyenovia Inc. (EYEN) - Market Cap to Future Revenue Ratio|GHSI - Price-to-Projected Revenue Ratio|OCUP (ocuphire.com) - Market Cap to Projected Revenue|OPT: Forward P/S Multiple